Research News

Immunotherapy as treatment for gastric or esophageal adenocarcinoma (GEAC)

Summary

The combination of chemotherapy (or targeted therapy) with immunotherapy is emerging rapidly as a promising strategy in the first line treatment against several tumor types. This study led by Dr Raghav Sundar provides the basis to further optimise treatment options for first-line metastatic GEAC patients using combination of Immunotherapy and chemotherapy.

 

Link to article: https://bit.ly/35WzvHy

 

Share this story:
Facebook
Twitter
LinkedIn

Related Research News

Research News

Genetic Testing in Asian Cancer Patients: Early Detection and Prevention

Multiple primary cancers (MPC) often indicate a hereditary cancer predisposition syndrome. In a study led by Prof Lee Soo Chin, …

Read More →
Research News

Predicting CLL Treatment with BCL-2 Dependence

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow, leading to the buildup …

Read More →
Research News

One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera

Muscle is our first line of defence against cancer. A randomised clinical trial in Singapore, led by N2CR members A/Prof …

Read More →